Home › Kanser sa Esophagus › Massachusetts › Boston
Pag-aaral pangklinika para sa Kanser sa Esophagus sa Boston, MA
Isang pag-aaral para sa Kanser sa Esophagus ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Boston. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Nagre-recruitPhase 2
- Dana-Farber Cancer Institute - Oncology Department, Boston
Distance-Based Exercise to Preserve Function and Prevent Disability
Nagre-recruit
- Dana-Farber Cancer Institute, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Nagre-recruitPhase 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1 Study of IM-1617 in Participants With Advanced Cancer
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Nagre-recruitPhase 1/2
- Tufts Medical Center, Boston
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Nagre-recruitPhase 2
- Massachusetts General Hospital (Data Collection Only), Boston
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Nagre-recruitPhase 1/2
- Dana Farber Cancer Institute, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
Nagre-recruitPhase 3
- Massachusetts General Hospital, Boston
Resilience and Equity in Aging, Cancer, and Health (REACH)
Nagre-recruit
- Dana-Farber Cancer Institute, Boston
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Dana Farber Cancer Institute, Boston
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Nagre-recruitPhase 3
- Research Site, Boston
Serial MRI Scans During Radiation Therapy
Nagre-recruit
- Brigham and Women Hospital, Boston
- Dana Farber Cancer Institute, Boston
Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEA
Nagre-recruitPhase 2
- Massachusetts General Hospital, Boston
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
Nagre-recruitPhase 1
- Mass General Cancer Center, Boston
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital Cancer Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Nagre-recruitPhase 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- at 2 pa
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
Nagre-recruitPhase 1/2
- Massachusetts General Hospital, Boston
Pag-aaral para sa Kanser sa Esophagus sa ibang lungsod
- Houston, TX36 pag-aaral
- New York City, NY22 pag-aaral
- Nashville, TN19 pag-aaral
- St. Louis, MO17 pag-aaral
- Pittsburgh, PA15 pag-aaral
- Los Angeles, CA15 pag-aaral
- Baldwin Park, CA14 pag-aaral
- Grand Rapids, MI14 pag-aaral
- Philadelphia, PA13 pag-aaral
- San Antonio, TX12 pag-aaral
- Dallas, TX11 pag-aaral
- Rochester, MN11 pag-aaral
Iba pang pag-aaral sa Boston
- Kanser sa Suso112 pag-aaral
- Non-Small Cell Lung Cancer90 pag-aaral
- Kanser (lahat ng uri)85 pag-aaral
- Metastatic Cancer63 pag-aaral
- Colorectal Cancer63 pag-aaral
- Kanser sa Baga62 pag-aaral
- Kanser sa Ovary61 pag-aaral
- Kanser sa Prostate59 pag-aaral
- Depression52 pag-aaral
- Kanser ng Endometrium50 pag-aaral
- Pagkabigo ng Puso44 pag-aaral
- Acute Myeloid Leukemia44 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.